iShares MSCI Japan ETF vs Viatris Inc — how do they compare? iShares MSCI Japan ETF trades at $97.86 (market cap $23.87B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: iShares MSCI Japan ETF is the larger of the two by market cap, and Viatris Inc pays a 2.75% dividend while iShares MSCI Japan ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 56 Days and Viatris Inc for 57 Days on average.
| EWJ | VTRS | |
|---|---|---|
Market Cap | $23.87B | $20.03B |
Volume | 5,412,820 | 14,109,977 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.32 | $18.27 |
52-Week Low | $78.36 | $9.74 |
Typical Hold Time | 56 Days | 57 Days |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $97.32, down 1.02% over the past day amid broader Asian market volatility. Technical indicators are mixed, with a neutral overall signal and bullish moving averages, while key support sits at $96. Recent news highlights Japan's monetary policy shifts, including BOJ rate hikes and yen fluctuations, influencing ETF performance as international equities show strength relative to the S&P 500.
The outlook for EWJ hinges on Japan's economic trajectory and central bank actions, with potential upside from continued international equity outperformance. Risks include rising bond yields, fiscal uncertainties, and currency volatility, warranting caution for investors seeking exposure to Japanese markets through this ETF.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.
The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →